ATE247653T1 - Thiazolidindionderivat und seine verwendung als antidiabetikum - Google Patents

Thiazolidindionderivat und seine verwendung als antidiabetikum

Info

Publication number
ATE247653T1
ATE247653T1 AT00920889T AT00920889T ATE247653T1 AT E247653 T1 ATE247653 T1 AT E247653T1 AT 00920889 T AT00920889 T AT 00920889T AT 00920889 T AT00920889 T AT 00920889T AT E247653 T1 ATE247653 T1 AT E247653T1
Authority
AT
Austria
Prior art keywords
antidiabetic drug
thiazolidinedione derivative
thiazolidinedione
derivative
antidiabetic
Prior art date
Application number
AT00920889T
Other languages
English (en)
Inventor
Paul D J Blackler
Robert Gordon Giles
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE247653(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE247653T1 publication Critical patent/ATE247653T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
AT00920889T 1999-04-23 2000-04-19 Thiazolidindionderivat und seine verwendung als antidiabetikum ATE247653T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical
PCT/GB2000/001514 WO2000064892A2 (en) 1999-04-23 2000-04-19 Thiazolidinedione derivative and its use as antidiabetic

Publications (1)

Publication Number Publication Date
ATE247653T1 true ATE247653T1 (de) 2003-09-15

Family

ID=26315460

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02080320T ATE382046T1 (de) 1999-04-23 2000-04-19 Herstellung einer polymorphen form eines thiazolidindionderivates
AT00920889T ATE247653T1 (de) 1999-04-23 2000-04-19 Thiazolidindionderivat und seine verwendung als antidiabetikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02080320T ATE382046T1 (de) 1999-04-23 2000-04-19 Herstellung einer polymorphen form eines thiazolidindionderivates

Country Status (40)

Country Link
US (2) US6815457B1 (de)
EP (3) EP1284268B1 (de)
JP (1) JP2002543075A (de)
KR (1) KR100744359B1 (de)
CN (1) CN1208335C (de)
AP (1) AP1495A (de)
AR (2) AR023568A1 (de)
AT (2) ATE382046T1 (de)
AU (1) AU765498B2 (de)
BG (1) BG65427B1 (de)
BR (1) BR0009934A (de)
CA (1) CA2370258A1 (de)
CO (1) CO5170424A1 (de)
CY (1) CY1107238T1 (de)
CZ (1) CZ20013799A3 (de)
DE (2) DE60037602T2 (de)
DK (2) DK1173434T3 (de)
DZ (1) DZ3155A1 (de)
EA (1) EA004534B1 (de)
ES (2) ES2204557T3 (de)
HK (1) HK1045154B (de)
HR (1) HRP20010773B1 (de)
HU (1) HUP0200929A3 (de)
IL (1) IL146110A0 (de)
MA (1) MA26785A1 (de)
MX (1) MXPA01010820A (de)
MY (1) MY128007A (de)
NO (1) NO320589B1 (de)
NZ (1) NZ515163A (de)
OA (1) OA11871A (de)
PE (1) PE20010040A1 (de)
PL (1) PL351686A1 (de)
PT (2) PT1173434E (de)
RS (1) RS50114B (de)
SK (1) SK286423B6 (de)
TR (1) TR200103061T2 (de)
TW (1) TW591027B (de)
UA (1) UA67843C2 (de)
UY (1) UY26120A1 (de)
WO (1) WO2000064892A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AR023561A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
CA2426117A1 (en) * 2000-09-26 2002-04-04 Dr. Reddy's Laboratories Limited Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (de) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphe Formen von Rosiglitazon Maleat
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (de) * 2004-01-28 2006-10-11 Usv Limited Verfahren zur herstellung von 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]phenylmethyl]thiazolidin-2,4-dionmaleat
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (de) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Verfahren zur Herstellung fester Dosierungsformen von Rosiglitazonmaleat

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
WO1995021608A1 (en) 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
WO1998057635A1 (en) 1997-06-18 1998-12-23 Smithkline Beecham Plc Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
EP1671637A3 (de) 1997-06-18 2007-12-19 SmithKline Beecham P.L.C. Behandlung der Diabetes mit Thiazolidindione und Sulphonylurea
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
TR199903057T2 (xx) 1997-06-18 2000-04-21 Smithkline Beecham Plc Diabetin tiazolidinedion ve metformin ile tedavisi.
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
CZ20013801A3 (cs) 1999-04-23 2002-07-17 Smithkline Beecham Plc Nový léčivý přípravek
AR023561A1 (es) 1999-04-23 2002-09-04 Smithkline Beecham Corp Una forma polimorfica del acido maleico de un derivado de tiazolidin-2, 4 diona, una composicion farmaceutica y el uso de dicho polimorfo para lafabricacion de un medicamento
HRP20010773B1 (en) 1999-04-23 2005-06-30 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CA2426117A1 (en) 2000-09-26 2002-04-04 Dr. Reddy's Laboratories Limited Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
EP1173434A2 (de) 2002-01-23
SK286423B6 (sk) 2008-09-05
CN1355801A (zh) 2002-06-26
CA2370258A1 (en) 2000-11-02
EP1284268B1 (de) 2007-12-26
DK1284268T3 (da) 2008-04-28
DZ3155A1 (fr) 2000-11-02
HUP0200929A2 (en) 2002-08-28
EA004534B1 (ru) 2004-06-24
HK1055293A1 (en) 2004-01-02
AR023568A1 (es) 2002-09-04
MA26785A1 (fr) 2004-12-20
KR100744359B1 (ko) 2007-07-30
EP1903043A1 (de) 2008-03-26
DE60037602D1 (de) 2008-02-07
PL351686A1 (en) 2003-06-02
HK1045154A1 (en) 2002-11-15
CZ20013799A3 (cs) 2002-04-17
EP1284268A1 (de) 2003-02-19
UA67843C2 (uk) 2004-07-15
HUP0200929A3 (en) 2004-03-29
MY128007A (en) 2007-01-31
MXPA01010820A (es) 2002-06-04
DK1173434T3 (da) 2003-12-08
RS50114B (sr) 2009-03-25
CY1107238T1 (el) 2012-11-21
HRP20010773B1 (en) 2005-06-30
PT1173434E (pt) 2003-12-31
NO320589B1 (no) 2005-12-27
US6815457B1 (en) 2004-11-09
EA200101119A1 (ru) 2002-04-25
TW591027B (en) 2004-06-11
AU765498B2 (en) 2003-09-18
ES2204557T3 (es) 2004-05-01
ES2298327T3 (es) 2008-05-16
KR20020028873A (ko) 2002-04-17
ATE382046T1 (de) 2008-01-15
AP1495A (en) 2005-11-30
UY26120A1 (es) 2000-12-29
BR0009934A (pt) 2002-06-04
EP1173434B1 (de) 2003-08-20
YU75201A (sh) 2004-09-03
PE20010040A1 (es) 2001-03-10
WO2000064892A3 (en) 2001-01-25
OA11871A (en) 2006-03-27
BG106119A (en) 2002-05-31
JP2002543075A (ja) 2002-12-17
AU4130600A (en) 2000-11-10
NO20015149L (no) 2001-12-17
HRP20010773A2 (en) 2002-10-31
DE60037602T2 (de) 2009-01-08
WO2000064892A2 (en) 2000-11-02
DE60004658D1 (de) 2003-09-25
NZ515163A (en) 2004-02-27
TR200103061T2 (tr) 2002-05-21
US20040092555A1 (en) 2004-05-13
CO5170424A1 (es) 2002-06-27
HK1045154B (en) 2004-06-25
BG65427B1 (bg) 2008-07-31
CN1208335C (zh) 2005-06-29
PT1284268E (pt) 2008-03-10
AR023564A1 (es) 2002-09-04
IL146110A0 (en) 2002-07-25
SK14912001A3 (sk) 2002-02-05
DE60004658T2 (de) 2004-06-24
NO20015149D0 (no) 2001-10-22

Similar Documents

Publication Publication Date Title
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE60010333D1 (de) Substituierte oxazole und thiazole derivate als hppar-alpha aktivatore
DE60139477D1 (de) 2-cyanopyrrolidin-derivate und ihre verwendung als arzneimittel
DE60005973D1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE60020701D1 (de) Thiazol- und oxazol-derivate und ihre pharmazeutische verwendung
DE60004658D1 (de) Thiazolidindionderivat und seine verwendung als antidiabetikum
DE60001840D1 (de) Chinuclidin-derivate und deren verwendung als muscarin-m3-rezeptoren-liganden
ATA5422000A (de) Oximderivate und ihre verwendung als latente säuren
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60230591D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE254123T1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
ATE375987T1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DK1244641T3 (da) Thiazolylamid-derivater
DE60034713D1 (de) Chinolyl-propyl-piperidinderivate und deren Verwendung als antimikrobielle Wirkstoffe
DE60008239D1 (de) Indolylpiperidinderivate als antihistaminische und antiallergische mittel
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE50113867D1 (de) Neue indolderivate und deren verwendung als arzneimittel
ATE247109T1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
ATE268770T1 (de) Thiazolidindionderivat und seine verwendung als antidiabetikum
ATE221529T1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
IL146115A0 (en) Thiazolidinedione derivative and its use as antidiabetic
ATE262524T1 (de) Thiazolidindionderivat und seine verwendung als antidiabetikum
ATE316087T1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
ATE229016T1 (de) Substituierte heterocyclische benzocycloalkene und ihre verwendung als analgetisch wirksame substanzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1173434

Country of ref document: EP

REN Ceased due to non-payment of the annual fee